Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhiyi Bio Says Live Biotherapeutic for Diarrhea Passes Safety Test

publication date: Jul 9, 2024

Zhiyi Biotech of Guangzhou, a company developing live biotherapeutic products (LBPs), reported its heat-killed Bacteroides fragilis product for Chemotherapy-induced Diarrhea (CID) was well-tolerated in a US trial. The clinical study was a randomized, double-blind, placebo-controlled, sequential dose-escalation trial that examined the safety and tolerability of SK10 in 24 healthy adult subjects. All dose levels of SK10 were generally safe and well tolerated. Based on the results, Zhiyi will advance SK10 into a trial that tests the candidate in CID patients. Zhiyi’s lead product, SK08, is in a Phase III clinical trial to treat IBS-D, which puts it ahead of the other LBPs in China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here